Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
CASI CASI Pharmaceuticals	$1.40 -2.1%	$1.65	$1.09 ▼ $7.67	$17.59M	0.53	48,996 shs	26,805 shs
IPHYF Innate Pharma	$1.31	$1.57	$1.31 ▼ $1.95	$109.82M	0.5	38 shs	N/A
JNCE Jounce Therapeutics	$1.88	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	169,314 shs
SLDB Solid Biosciences	$5.26 -3.0%	$4.00	$2.41 ▼ $10.37	$420.13M	2.34	1.21 million shs	610,739 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-92.21%
CASI CASI Pharmaceuticals	-2.10%	+5.26%	-23.46%	-30.00%	-78.53%
IPHYF Innate Pharma	0.00%	-32.82%	-9.66%	-9.66%	-32.13%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
SLDB Solid Biosciences	-2.95%	+5.71%	+14.10%	+94.81%	-24.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1625 of 5 stars	3.8	0.0	0.0	0.0	0.6	0.0	0.0
CASI CASI Pharmaceuticals	4.26 of 5 stars	3.5	3.0	0.0	4.3	3.8	1.7	0.0
IPHYF Innate Pharma	0.4795 of 5 stars	0.0	5.0	0.0	0.0	0.0	1.7	0.0
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	3.1534 of 5 stars	4.6	1.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	185.71% Upside
IPHYF Innate Pharma	0.00	N/A	N/A	N/A
JNCE Jounce Therapeutics	0.00	N/A	N/A	N/A
SLDB Solid Biosciences	3.17	Buy	$15.10	187.07% Upside

Current Analyst Ratings Breakdown

Latest APTO, SLDB, IPHYF, JNCE, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
CASI CASI Pharmaceuticals	$28.54M	0.60	N/A	N/A	$0.12 per share	11.67
IPHYF Innate Pharma	$21.77M	5.04	N/A	N/A	$0.11 per share	11.91
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53
SLDB Solid Biosciences	$8.09M	50.40	N/A	N/A	$3.43 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
IPHYF Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest APTO, SLDB, IPHYF, JNCE, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
CASI CASI Pharmaceuticals	N/A	0.81	0.68
IPHYF Innate Pharma	N/A	2.60	2.60
JNCE Jounce Therapeutics	N/A	8.37	8.37
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
CASI CASI Pharmaceuticals	22.23%
IPHYF Innate Pharma	N/A
JNCE Jounce Therapeutics	80.66%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
CASI CASI Pharmaceuticals	21.24%
IPHYF Innate Pharma	31.89%
JNCE Jounce Therapeutics	6.92%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
IPHYF Innate Pharma	179	83.83 million	57.10 million	Not Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable

APTO, SLDB, IPHYF, JNCE, and CASI Headlines

Recent News About These Companies

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10 at 8:00 AM | prnewswire.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10 at 4:43 AM | seekingalpha.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10 at 4:43 AM | investing.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10 at 4:43 AM | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10 at 4:43 AM | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9 at 2:59 AM | msn.com

SLDB - Solid Biosciences Inc Price vs Fair Value - Morningstar

July 8, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at Citigroup

June 27, 2025 | marketbeat.com

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC Wainwright

June 17, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

APTO, SLDB, IPHYF, JNCE, and CASI Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

CASI Pharmaceuticals NASDAQ:CASI

$1.40 -0.03 (-2.10%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$1.32 -0.08 (-5.36%)

As of 07/11/2025 04:59 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Innate Pharma OTCMKTS:IPHYF

$1.31 0.00 (0.00%)

As of 07/11/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Jounce Therapeutics NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Solid Biosciences NASDAQ:SLDB

$5.26 -0.16 (-2.95%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$5.27 +0.01 (+0.21%)

As of 07/11/2025 06:26 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time